Copyright
©The Author(s) 2026.
World J Gastrointest Endosc. Jan 16, 2026; 18(1): 114791
Published online Jan 16, 2026. doi: 10.4253/wjge.v18.i1.114791
Published online Jan 16, 2026. doi: 10.4253/wjge.v18.i1.114791
Table 1 Baseline characteristics of the propensity-matched groups, mean ± SD
| Indicator | LPD group (n = 50) | OPD group (n = 50) | t/χ2 | P value |
| Gender (male/female) | 27/23 | 26/24 | 0.02 | 0.89 |
| Age (years) | 62.5 ± 7.2 | 63.1 ± 6.8 | -0.49 | 0.62 |
| BMI (kg/m2) | 24.2 ± 3.1 | 24.5 ± 3.0 | -0.52 | 0.61 |
| Tumor size (cm) | 2.8 ± 0.9 | 2.9 ± 1.0 | -0.38 | 0.71 |
| ASA score (I/II/III) | 2/34/14 | 1/35/14 | 0.45 | 0.80 |
| Diabetes (no/yes) | 36/14 | 35/15 | 0.05 | 0.82 |
Table 2 Perioperative outcomes, mean ± SD
| Indicator | LPD group (n = 50) | OPD group (n = 50) | t/χ2 | P value | MD/OR (95%CI) |
| Operative time (minutes) | 320 ± 45 | 285 ± 40 | 4.12 | < 0.001 | MD 35 (18.31 to 51.69) |
| Blood loss (mL) | 180 ± 60 | 350 ± 90 | -11.2 | < 0.001 | MD -170 (-199.98 to -140.02) |
| Transfusion (no/yes) | 46/4 | 39/11 | 4.65 | 0.03 | OR 0.31 (0.09 to 1.05) |
| LOS (days) | 12 ± 3 | 15 ± 4 | -3.28 | 0.002 | MD -3 (-4.39 to -1.61) |
| Overall complications (no/yes) | 29/21 | 25/25 | 0.68 | 0.41 | OR 0.72 (0.33 to 1.59) |
| Severe complications (CD ≥ III, no/yes) | 42/8 | 39/11 | 0.77 | 0.38 | OR 0.68 (0.25 to 1.85) |
| Pancreatic fistula (no/yes) | 44/6 | 42/8 | 0.32 | 0.58 | OR 0.72 (0.23 to 2.24) |
| DGE (no/yes) | 45/5 | 43/7 | 0.41 | 0.52 | OR 0.68 (0.20 to 2.32) |
| 90-day readmission (no/yes) | 49/1 | 47/3 | 1.02 | 0.30 | OR 0.32 (0.03 to 3.18) |
| 90-day mortality (no/yes) | 49/1 | 48/2 | 0.24 | 0.62 | OR 0.49 (0.04 to 5.58) |
Table 3 Oncologic outcomes, mean ± SD
| Indicator | LPD group (n = 50) | OPD group (n = 50) | t/χ2 | P value | MD/OR/HR (95%CI) |
| Lymph nodes retrieved | 14 ± 5 | 13 ± 4 | 0.75 | 0.45 | MD 1 (-0.77 to 2.77) |
| R0 resection (no/yes) | 4/46 | 6/44 | 0.34 | 0.56 | OR 1.57 (0.41 to 5.93) |
| Median OS [months (95%CI)] | 22 (19-25) | 20 (17-23) | 0.65 | HR 0.92 (0.65 to 1.31) | |
| 12-month RFS (%) | 78 | 72 | 0.48 | HR 0.78 (0.35 to 1.74) | |
| Adjuvant completion (no/yes) | 8/42 (84%) | 10/40 (80%) | 0.24 | 0.62 | OR 1.31 (0.47 to 3.66) |
- Citation: Kalim M, Sarwar M, Chishti SSA, Ali M, Qayyum S, Ahmed J, Memon M, Shenawa E. Comparative outcomes of laparoscopic vs open pancreaticoduodenectomy in early-stage pancreatic cancer. World J Gastrointest Endosc 2026; 18(1): 114791
- URL: https://www.wjgnet.com/1948-5190/full/v18/i1/114791.htm
- DOI: https://dx.doi.org/10.4253/wjge.v18.i1.114791
